Health Care·Biotechnology·$2.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.30 | N/A | -8.33% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.30 | N/A | -8.33% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook without offering specific guidance. They emphasized their commitment to pipeline development.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its pipeline despite the current challenges.
Sarepta Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue data and forward guidance may leave investors uncertain about the company's near-term performance. The stock's minor drop reflects cautious sentiment in response to the earnings report.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TENET HEALTHCARE COR
Feb 22, 2016